SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation

  1. Morihiro Matsuda1,
  2. Bobby S. Korn1,
  3. Robert E. Hammer2,
  4. Young-Ah Moon1,
  5. Ryutaro Komuro1,
  6. Jay D. Horton1,
  7. Joseph L. Goldstein1,3,4,
  8. Michael S. Brown1,3,5, and
  9. Iichiro Shimomura1
  1. 1Department of Molecular Genetics, 2Howard Hughes Medical Institute and Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9046, USA

Abstract

In liver, the synthesis of cholesterol and fatty acids increases in response to cholesterol deprivation and insulin elevation, respectively. This regulatory mechanism underlies the adaptation to cholesterol synthesis inhibitors (statins) and high calorie diets (insulin). In nonhepatic cells, lipid synthesis is controlled by sterol regulatory element-binding proteins (SREBPs), membrane-bound transcription factors whose active domains are released proteolytically to enter the nucleus and activate genes involved in the synthesis and uptake of cholesterol and fatty acids. SCAP (SREBP cleavage-activating protein) is a sterol-regulated escort protein that transports SREBPs from their site of synthesis in the endoplasmic reticulum to their site of cleavage in the Golgi. Here, we produced a conditional deficiency of SCAP in mouse liver by genomic recombination mediated by inducible Cre recombinase. SCAP-deficient mice showed an 80% reduction in basal rates of cholesterol and fatty acid synthesis in liver, owing to decreases in mRNAs encoding multiple biosynthetic enzymes. Moreover, these mRNAs failed to increase normally in response to cholesterol deprivation produced by a cholesterol synthesis inhibitor and to insulin elevation produced by a fasting–refeeding protocol. These data provide in vivo evidence that SCAP and the SREBPs are required for hepatic lipid synthesis under basal and adaptive conditions.

Keywords

Footnotes

  • 3 Corresponding authors.

  • 4 E-MAIL ; FAX (214) 648-8804.

  • 5 E-MAIL ; FAX (214) 648-8804.

  • Article and publication are at www.genesdev.org/cgi/doi/10.1101/gad.891301.

    • Received February 26, 2001.
    • Accepted March 21, 2001.
| Table of Contents

Life Science Alliance